AI Summary
- Patients self-treated benzodiazepine withdrawal with bovine adrenal cortex supplements despite absence of evidence.
- Supplements pose risks: adrenal axis disruption, contamination, variable potency, and potential interactions complicating withdrawal management.
- Clinicians should inquire about supplement use, provide evidence-based benzodiazepine tapering, and monitor for endocrine and pharmacologic complications.
Prim Care Companion CNS Disord. 2026 Nov 5;28(6):26cr04286. doi: 10.4088/PCC.26cr04286.
NO ABSTRACT
PMID:42987125 | DOI:10.4088/PCC.26cr04286
Share Evidence Blueprint
Save to Google Notes
Search Google Scholar
Save as PDF
⭐ My Revision List
